Exploring the Benefits of Ruxolitinib in Second-Line Polycythemia Vera
Srdan Verstovsek, MD, PhD, discusses the use of ruxolitinib as a second-line treatment of patients with polycythemia vera.
Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the use of ruxolitinib (Jakafi) as a second-line treatment for patients with polycythemia vera (PV).
For the second-line setting in PV, patients typically have a shorter survival, said Verstovsek. At this stage, the disease is more aggressive and a second line of therapy is needed.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
